Trials / Recruiting
RecruitingNCT07321106
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
A Phase 1, First-in-human (FIH), Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Cartography Biosciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
Conditions
- Colorectal Cancer
- Colorectal Cancer (CRC)
- Colorectal (Colon or Rectal) Cancer
- CRC
- Metastatic Colon Cancer
- Colon Cancer
- Advanced Colorectal Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CBI-1214 | CBI-1214 is a bispecific T cell engager that binds to LY6G6D and CD3. It is designed to link the patients T cells to cancer cells and to mediate tumor cell killing. LY6G6D is an emerging target specifically expressed on malignant colorectal cancer cells. |
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2029-04-01
- Completion
- 2029-10-01
- First posted
- 2026-01-06
- Last updated
- 2026-03-03
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07321106. Inclusion in this directory is not an endorsement.